*Purpose: Non-alcoholic Fatty Liver Disease (NAFLD) afflicts ~20-40% people in the western world and is a risk factor for comorbidities prevalent in the lung transplant setting. We performed a retrospective analysis to assess whether NAFLD confers additional risk of untoward outcomes one-year post-transplant.

*Methods: Patients aged >18 years who underwent lung transplantation at Brigham and Women’s Hospital between 1/1/2015 – 10/01/2017 were included. NAFLD was diagnosed via abdominal ultrasound; patients then underwent staging Fibroscan or Fibrosure studies. Statistical analysis was performed using STATA version 15. 1 (StatCorp LLC, College Station, TX).

*Results: NAFLD was identified in 22% (31/141) of our cohort; 29%, 60%, 5%, 3% and 3% of patients with NAFLD had stage F0, F0-1, F2, F3 and F4 fibrosis, respectively. NAFLD was significantly associated with male gender, advanced age, BMI and pre-transplant hyperlipidemia (p=0.039, 0.019, 0.011, and 0.013, resp.). NAFLD had no adverse effect on post-transplant outcomes by univariate analysis; NAFLD was associated with improved index ICU and hospital length of stay (LOS) and preservation of pre-transplant serum creatinine (Table 1). These remained significant on multivariate analysis (Table 2). One-year survival was 93.5% (29/31) in patients with NAFLD and 92.7% (102/110) in patients without.

*Conclusions: Patients with NAFLD have excellent one-year outcomes post- lung transplantation. Surprisingly, patients with NAFLD had shorter index ICU and hospital LOS and greater preservation of renal function. To our knowledge this is the first study to report on outcomes of lung transplant recipients with NAFLD.

« Back to 2019 American Transplant Congress